Drugs in MeSH Category Topoisomerase II Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	DOXORUBICIN HYDROCHLORIDE	doxorubicin hydrochloride	INJECTABLE;INJECTION	050467-004	Jul 22, 1987		DISCN	No	No
Fresenius Kabi Usa	EPIRUBICIN HYDROCHLORIDE	epirubicin hydrochloride	INJECTABLE;INJECTION	065408-002	Oct 15, 2007		DISCN	No	No
Ortho Mcneil Pharm	FLOXIN IN DEXTROSE 5%	ofloxacin	INJECTABLE;INJECTION	020087-001	Mar 31, 1992		DISCN	No	No
Teva	LEVOFLOXACIN	levofloxacin	TABLET;ORAL	076361-002	Jun 20, 2011	AB	RX	No	No
Lupin	DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)	doxorubicin hydrochloride	INJECTABLE, LIPOSOMAL;INJECTION	215178-002	Jul 16, 2024	AB	RX	No	No
Glenmark Pharms Ltd	LEVOFLOXACIN	levofloxacin	TABLET;ORAL	200250-003	Jun 20, 2011	AB	RX	No	No
Santen	IQUIX	levofloxacin	SOLUTION/DROPS;OPHTHALMIC	021571-001	Mar 1, 2004		DISCN	Yes	No

Market Dynamics and Patent Landscape for NLM MeSH “Topoisomerase II Inhibitors” Drugs (2026): Exclusivity, Generic/Biosimilar Risk, and Litigation Hotspots

Last updated: June 4, 2026

The MeSH category “Topoisomerase II inhibitors” covers small-molecule anticancer agents that target the ATP/ DNA strand passage step of Topoisomerase II. Patent and exclusivity risk is concentrated in a small set of widely used drugs, led commercially by anthracyclines (doxorubicin/pegylated liposomal doxorubicin), epipodophyllotoxins (etoposide, teniposide), and topo II–targeting intercalators (mitoxantrone; mitoxantrone has stable but dated exclusivity positions). Patent estates are dominated by formulation, salt/particle size, device-like delivery, and method-of-use claims rather than new active-ingredient coverage for legacy molecules. New entry risk for generics depends on whether Orange Book listings include unexpired formulation or method-of-use patents, and whether Paragraph IV challenges have already triggered settlements.

Which topoisomerase II inhibitors are marketed in the US, and where do patents drive revenue exposure?

Topoisomerase II inhibitor revenue is split between:

• Cytotoxic intravascular anthracyclines (doxorubicin and derivatives).
• Etoposide-based regimens (etoposide, etoposide phosphate, and branded/authorized forms).
• Teniposide (more limited footprint, more region-specific and clinic-dependent).
• Mitoxantrone (oncology and autoimmune/neuro indications in some geographies, US footprint more oncology-linked).

Market concentration effect: For most MeSH-class agents, the active ingredient is old enough that primary composition-of-matter coverage is largely expired. The patent “gates” that still matter are:

1. Formulation patents (liposomes, pegylated products, particle size, lyophilized cakes).
2. Method-of-use patents (combination regimens, dosing schedules, specific line-of-therapy or biomarker-enriched populations).
3. Manufacturing process patents (rare for entry blockers unless tied to regulatory exclusivity and Orange Book listings).

Key commercial/filing clusters within Topoisomerase II inhibitors

• Pegylated liposomal doxorubicin (PLD): dense formulation patent estates and manufacturing method filings are the principal barrier to generic substitution for the PLD product line.
• Etoposide and etoposide phosphate: generics dominate where Orange Book coverage is narrow or already worked through via Paragraph IV.
• Teniposide: smaller market; patent risk is usually tied to any remaining Orange Book-listed formulation/method-of-use patents for specific authorized presentations.
• Mitoxantrone: most barriers are historical; ongoing risk can persist via residual formulation or method-of-use listings.

What patents protect doxorubicin and pegylated liposomal doxorubicin (PLD) in the US?

For doxorubicin, the active ingredient is broadly generic in the US. The more defensible patent landscape sits in pegylated liposomal doxorubicin, where the delivery system creates patentable formulation and manufacturing pathways.

PLD: what patent types typically remain

Featured-snippet answer: PLD exclusivity and patent leverage in practice are usually tied to liposome formulation/manufacturing parameters and specific method-of-use claims that remain Orange Book-listed.

Common claim families mapped to PLD strategy:

• Liposome size distribution, encapsulation efficiency, and pegylated surface chemistry.
• Lyophilized vs ready-to-use product form.
• Manufacturing process steps that control leakage and stability.
• Method-of-use: combinations with other oncology agents, line-of-therapy, or specific indication expansions.

How does PLD patent coverage translate into generic entry barriers?

• Generic entry requires a product to be substitutable under FDA standards and avoid infringement of Orange Book-listed claims.
• If Orange Book lists formulation and method-of-use patents, generics may need a Section viii(b)(4) carve-out or generic design-around that keeps them noninfringing.
• Settlement-driven outcomes often create “at-risk windows” aligned with patent-specific triggers.

When does pegylated liposomal doxorubicin lose exclusivity, and what generic launch scenarios exist?

Featured-snippet answer: For PLD, the relevant “lose exclusivity” timeline is not a single date. It is the combination of:

• expiration of formulation and method-of-use patents listed in the Orange Book, plus
• any pediatric exclusivity or regulatory exclusivity if tied to specific approvals.

Market impact of multiple blockers: If PLD has multiple Orange Book patents in force, a generic may be delayed until the last relevant patent expires or is cleared via Paragraph IV litigation and settlement.

Generic launch scenarios for PLD-type barriers

1. Clean expiry: last Orange Book-listed patent expires and generic launches immediately at statutory allowance.
2. Paragraph IV settlement: payer and manufacturer dynamics lock in launch at a settlement-trigger date.
3. Design-around: generic attempts non-infringing formulation or avoids method claims, risking infringement suits.
4. Indication-specific launch: generic may launch for a subset of indications where patents have expired or are not listed.

What patents protect etoposide and etoposide phosphate, and how many Orange Book patents block entry?

Featured-snippet answer: For etoposide-class agents, Orange Book blockers typically cluster in specific authorized presentations (e.g., phosphate salts or ready-to-use formats) and in any remaining formulation/method-of-use listings. Active ingredient protection generally does not provide meaningful remaining exclusivity.

Where patent density usually concentrates

• Etoposide phosphate: salts and presentation can carry distinct patent listings tied to stability and manufacturing controls.
• Lyophilized and reconstituted-ready presentations: formulation/processing patents persist longer than composition-of-matter.
• Method-of-use: combinations with platinum agents and line-of-therapy expansions sometimes keep method patents relevant longer than expected.

How many patents matter in practice

• Market entry is governed by the set of Orange Book patents listed for the specific listed drug and strength form.
• The practical question for investors and litigators is not “how many patents exist,” but “how many are asserted in litigation or explicitly listed for the specific NDA/NDC presentations used by customers.”

When does etoposide lose exclusivity, and what generic entry risks exist for etoposide regimens?

Featured-snippet answer: Etoposide generics generally face limited remaining entry risk because multiple authorized generic products already exist, and historical patents usually expired. The remaining risk is presentation-specific and arises from any still-listed formulation/method patents for specific NDCs.

What shifts the risk profile

• FDA switching from branded to generic NDCs driven by formulary and purchasing.
• Hospital drug spend policies that substitute by dosage form rather than label claim alone.
• Any brand-driven lifecycle management: line extension filings, new strengths, or presentation reformulations.

What patents protect teniposide, and why is patent leverage usually narrower than etoposide?

Featured-snippet answer: Teniposide’s patent leverage is narrower because market penetration is smaller and regulatory portfolios are typically less expansive. Where patents persist, they tend to attach to specific formulations or specific method-of-use claims.

Commercial dynamics

• Teniposide use is regimens- and oncology-portfolio-driven.
• Substitution depends on supply continuity and hospital protocol preferences.
• Patent leverage is often less about delaying generic entry for years and more about keeping branded presentation preferred.

Mitoxantrone: what patents protect it and what exclusivity timelines matter?

Featured-snippet answer: Mitoxantrone’s remaining patent leverage in the US is usually limited to residual formulation or method-of-use listings tied to specific authorized presentations. Active ingredient exclusivity is not usually the bottleneck in 2026.

Why mitoxantrone often behaves like a “settled” generic market

• Multiple approvals and widely available generics.
• Manufacturing processes are established.
• Any remaining patent protection usually requires granular checking of Orange Book listings per strength/presentation.

How does Paragraph IV litigation shape the patent landscape for topoisomerase II inhibitors?

Featured-snippet answer: Paragraph IV challenges for topoisomerase II inhibitors usually target Orange Book-listed formulation and method-of-use patents on brand-specific presentations. For long-established actives, litigation tends to be fewer in number, more concentrated in PLD-like delivery systems, and more outcome-dependent on settlement dates than on final trial outcomes.

What patterns repeatedly show up

• If the brand has a thick PLD-style formulation and manufacturing estate, generics tend to settle rather than litigate to judgment.
• Method-of-use claims can be harder to design around because they map directly to standard clinical combinations or dosing schedules used in pivotal practice.

What is the Orange Book status of major topoisomerase II inhibitors, and which patent types remain?

Featured-snippet answer: For legacy topoisomerase II drugs, Orange Book coverage typically persists through formulation and method-of-use patents, not composition-of-matter.

Patent-type prevalence by drug class (practical mapping for business decisions)

Drug (MeSH class)	Typical surviving Orange Book listing type	Business implication for generics
Pegylated liposomal doxorubicin	Formulation + method-of-use	Higher settlement likelihood; harder design-around
Doxorubicin (non-PLD)	Often limited to specific presentations	Faster generic substitution
Etoposide / etoposide phosphate	Formulation (presentation) + some method-of-use	Entry depends on NDC-level listings
Teniposide	Narrow set, presentation-dependent	Smaller market reduces strategic incentive
Mitoxantrone	Residual formulation/method listings	Often behaves like established generic competition

Which companies are challenging topoisomerase II inhibitor patents, and what does “at-risk” entry look like?

Featured-snippet answer: In the MeSH topoisomerase II inhibitor space, generic and biosimilar-oriented challengers are primarily expected for branded presentation barriers (notably PLD), while established generic manufacturers dominate plain etoposide and teniposide. Settlement-driven at-risk entries tend to align with the expiration of the last relevant Orange Book patent for the exact NDC in use.

At-risk entry indicators used by market participants

• Paragraph IV filing date relative to expected patent expiry.
• Court docket activity and status of any stay or settlement agreement.
• Whether the challenged claims are formulation (design-around difficult) versus method-of-use (may require carve-out).

How strong is the patent estate for topoisomerase II inhibitors (product-by-product lens)?

Featured-snippet answer: Patent strength is highest for delivery-system-specific products like PLD, moderate for presentation-specific salts/formulations (etoposide phosphate variants), and weakest for plain active-ingredient drugs where composition-of-matter is largely expired.

Investment/litigation lens

• Strongest estates: delivery systems with many formulation and manufacturing claims.
• Medium estates: salt form and presentation-related formulation patents.
• Weakest estates: old actives with few remaining Orange Book patents and broad generic availability.

Formulation vs method-of-use: which patent category blocks generic substitution more effectively?

Featured-snippet answer: For topoisomerase II inhibitors, formulation patents typically block substitution more effectively when the formulation is tightly coupled to FDA-listed product identity (NDC-level) and manufacturing controls are not easily replicated. Method-of-use patents can block launch too, but design-around may be possible if a generic can avoid practicing the claimed regimen, subject to FDA labeling and infringement risk.

Why this matters for market dynamics

• Formulation blockers create supply and product identity constraints.
• Method-of-use blockers create clinical practice constraints and reimbursement/prescriber behavior constraints.

What formulation patents are most common in topo II inhibitor lifecycle management?

Featured-snippet answer: The most common formulation patents involve:

• liposome characteristics (for PLD-like products),
• salt form and stability controls (for etoposide phosphate-like variants),
• lyophilized vs liquid presentation and reconstitution parameters,
• and manufacturing process parameters tied to stability and encapsulation.

How do patent expirations translate into pricing pressure for hospitals and distributors?

Featured-snippet answer: Patent expiry triggers rapid pricing pressure when multiple generic alternatives exist and when tender processes accept NDC substitution. The largest pricing resets occur for products where branded manufacturing is costlier and where generic NDCs are immediately authorized.

Mechanism

• Loss of exclusivity for the most protected NDC drives channel substitution.
• Formulary and contract pricing converts quickly when purchasing committees treat the drug as interchangeable at the protocol level.

Key takeaways

• Patent leverage in MeSH “topoisomerase II inhibitors” is usually concentrated in formulation and method-of-use patents rather than active ingredient composition-of-matter.
• Pegylated liposomal doxorubicin (PLD) typically shows the strongest remaining barrier due to delivery-system formulation complexity and dense Orange Book-linked claims.
• Etoposide and etoposide phosphate present a more “worked-through” generic landscape; remaining barriers are typically presentation- and NDC-level.
• Paragraph IV litigation outcomes in this class often hinge on whether challenged patents are formulation/manufacturing (harder to design around) or method-of-use (potentially carve-out-able, subject to infringement risk).
• Generic entry risk and timing are governed by Orange Book patent-by-patent timing and any settlement-triggered launch dates, not by the broad drug category alone.

FAQs

1) What is the Orange Book relevance for topoisomerase II inhibitor generics if composition-of-matter is expired?
Orange Book remains decisive because surviving formulation and method-of-use patents for the specific NDA/NDC presentation can still block launch even when the active ingredient is generically free.

2) Do etoposide phosphate generics face the same patent risk as PLD?
No. PLD typically has delivery-system formulation complexity that supports denser Orange Book listings; etoposide phosphate risk is usually presentation-specific and more likely to be narrower.

3) How do settlement agreements change generic launch timing for topoisomerase II inhibitors?
Settlements can set a fixed “carve-out” launch date or trigger earlier/later entry than the theoretical patent expiry, depending on stipulated dates, design-arounds, and permitted label changes.

4) What patent types are most likely to remain enforceable for decades in this category?
Delivery-system formulation and manufacturing patents, plus method-of-use claims tied to specific regimens, are the most persistent enforceable categories.

5) Are there biosimilar risks in MeSH “topoisomerase II inhibitors”?
This MeSH class is dominated by small molecules, so biosimilar frameworks generally do not apply. The relevant competitive risk is generic substitution and lifecycle management around formulations.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. NLM. MeSH (Medical Subject Headings): Topoisomerase II Inhibitors. National Library of Medicine.
3. FDA. Paragraph IV Certification and Dispute Resolution (Hatch-Waxman context). U.S. Food and Drug Administration.